Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 7 OMEN; Menogarol; NSC 269148; Tomosar; TUT 7; U 52047; UT 7

Latest Information Update: 04 Jul 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Taiho Pharmaceutical
  • Class Anthracyclines; Cytostatic antibiotics; Nogalamucins
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Breast cancer; Cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Malignant melanoma; Multiple myeloma; Myeloid leukaemia; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
  • Discontinued Lymphoma

Most Recent Events

  • 04 Jul 2006 No development reported - Phase-I for Cancer in Canada (unspecified route)
  • 04 Jul 2006 No development reported - Phase-II for Breast cancer in European Union (unspecified route)
  • 04 Jul 2006 No development reported - Phase-II for Cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top